Bidding 24-27 Aug 2026, price band ₹938–988, lot 15 shares.
GMP last updated: 1 Sept 2026, 9:36 AM IST
| Date | GMP (₹) | Est. Listing Price (₹) | Est. Listing Gain |
|---|---|---|---|
| 31 Aug | ₹185 | ₹1,173 | 18.72% |
| 30 Aug | ₹185 | ₹1,173 | 18.72% |
| 29 Aug | ₹240 | ₹1,228 | 24.29% |
| 28 Aug | ₹240 | ₹1,228 | 24.29% |
| 27 Aug | ₹265 | ₹1,253 | 26.82% |
| 26 Aug | ₹270 | ₹1,258 | 27.33% |
| 25 Aug | ₹285 | ₹1,273 | 28.85% |
| 24 Aug | ₹352 | ₹1,340 | 35.63% |
| 23 Aug | ₹335 | ₹1,323 | 33.91% |
| 22 Aug | ₹409 | ₹1,397 | 41.40% |
| 21 Aug | ₹410 | ₹1,398 | 41.50% |
| 20 Aug | ₹345 | ₹1,333 | 34.92% |
| 19 Aug | ₹300 | ₹1,288 | 30.36% |
| 18 Aug | ₹220 | ₹1,208 | 22.27% |
After allotment
| Category | Times | Est. Allotment Chances* |
|---|---|---|
| HNIs (Total) | 77.53🔥 | 1.3% |
| bHNI | 87.34🔥 | 1.1% |
| sHNI | 57.91🔥 | 1.7% |
| QIBs | 181.2🔥 | - |
| Retail | 13.52🔥 | 7.4% |
| Employees | 16.19🔥 | 6.2% |
| Total | 74.98🔥 | - |
*Rough estimate: 1 ÷ times subscribed. Retail and HNI allotment is by lottery, so actual odds depend on the number of applications.
Symbiotec Pharmalab is a pharmaceutical company engaged in developing and manufacturing active pharmaceutical ingredients, contract development and manufacturing solutions, and complex injectables. The company operates an integrated business model supported by research and development, fermentation, and organic chemistry capabilities. Its active pharmaceutical ingredient portfolio primarily focuses on steroidal products, while its contract development and manufacturing business offers development and manufacturing services for pharmaceutical, nutraceutical, and other life science companies. The company also develops complex injectable products, including double-chamber formats, and leverages its in-house active pharmaceutical ingredient capabilities to support these offerings. Revenue is generated through the sale of active pharmaceutical ingredients, contract development and manufacturing services, and complex injectable products. Its business is supported by backward integration in key raw material processing, large-scale fermentation capacity, and multiple manufacturing facilities, enabling it to serve customers across regulated and global markets.